Loading…
The patent covers compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof.
Ensysce Biosciences, Inc. (ENSC) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".
The patent, once granted, will protect Ensysce's innovative approach to developing safer amphetamine-based medications by incorporating enzyme-cleavable prodrugs and inhibitors.
Ensysce Biosciences has a free float of 14,684,200 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.